Therapeutic Arthritis Research and Gastrointestinal Event Trial of lumiracoxib - study design and patient demographics
Open Access
- 11 June 2004
- journal article
- clinical trial
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 20 (1), 51-63
- https://doi.org/10.1111/j.1365-2036.2004.02026.x
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- PHARMACOKINETICS AND METABOLISM OF LUMIRACOXIB IN HEALTHY MALE SUBJECTSDrug Metabolism and Disposition, 2004
- Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitorsGut, 2003
- The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitorsArthritis & Rheumatism, 2002
- Current perspective on the cardiovascular effects of coxibs.Cleveland Clinic Journal of Medicine, 2002
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000
- COX-2 inhibitorsThe Lancet, 1999
- Interim analysis: The alpha spending function approachStatistics in Medicine, 1994
- The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hipArthritis & Rheumatism, 1991
- The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the handArthritis & Rheumatism, 1990
- Development of criteria for the classification and reporting of osteoarthritis: Classification of osteoarthritis of the kneeArthritis & Rheumatism, 1986